A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/1998
11/18/1998	EP0878467A1 Substituted 6- and 7-aminotetrahydroisoquinolinecarboxylic acids
11/18/1998	EP0877806A1 Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
11/18/1998	EP0877804A1 Inhibitors of cell-cycle progression, and uses related thereto
11/18/1998	EP0877758A2 PURIFIED SR-p70 PROTEIN
11/18/1998	EP0877743A1 ((3"-thioxacyclohex-1"-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity
11/18/1998	EP0877615A1 Combination therapy method for treating cancer using edatrexate and a taxane derivative, e.g. paclitaxel
11/18/1998	EP0877614A1 Method for inducing death of neoplastic cells using piperazine oxirane derivatives
11/18/1998	EP0877608A1 SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
11/18/1998	EP0877605A2 Solid instant-release forms of administration and process for producing the same
11/18/1998	EP0724581B1 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
11/18/1998	CN1199045A Substituted 6- and 7-aminotetrahydroisoquinolinecarboxylic acids
11/18/1998	CN1040759C Carbo-acyclic nucleoside derivs. as antiviral and antineoplastic agents
11/18/1998	CN1040746C New crystalline form of vitamin D analogue
11/17/1998	US5837846 Biosynthetic binding proteins for immuno-targeting
11/17/1998	US5837824 Binds to monoclonal antibody bw 835, dsm acc 2022; use of epitope for diagnosis and therapy
11/17/1998	US5837696 Method of inhibiting cancer growth
11/17/1998	US5837690 Derivatives of triterpenoid acids and uses thereof.
11/17/1998	US5837680 Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
11/17/1998	US5837677 Method for the treatment of cancer with Exochelins of Mycobacterium tuberculosis
11/17/1998	US5837676 Use of scatter factor to enhance angiogenesis
11/17/1998	US5837673 Camptothecin derivatives
11/17/1998	US5837531 Recombinant adenoviruses for gene therapy in cancers
11/17/1998	US5837525 Polypeptides
11/17/1998	US5837510 Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
11/17/1998	US5837508 Hce3p83 polypeptides and polynucleotides used in the design of protocols for treatment of alzheimer's disease, stroke, cancer, inflammation, arthritis, musculoskeletal disease, heart disease, kidney disease and diagnostic assays for such
11/17/1998	US5837490 Therapeutic, diagnostic, research uses
11/17/1998	US5837462 Tumorigenic cell lines altered by genetic engineering and their use for the testing of antitumor drugs
11/17/1998	US5837451 Identifying composition which affect kinase activity
11/17/1998	US5837283 Cationic lipid compositions targeting angiogenic endothelial cells
11/17/1998	US5837279 Encapsulation of ionizable agents in liposomes
11/17/1998	US5837268 Immunogens; genetic engineering; noncytotoxic; antitumor agents for breast cancer
11/17/1998	US5837251 Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
11/17/1998	US5837248 Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide
11/17/1998	US5837244 Treating a cell proliferative disorder
11/17/1998	US5837243 Therapeutic compounds comprised of anti-Fc receptor antibodies
11/17/1998	US5837233 Method for treating tumors
11/17/1998	US5837231 GM-CSF administration for the treatment and prevention of recurrence of brain tumors
11/15/1998	CA2237450A1 Preparation having increased in vivo tolerability
11/13/1998	CA2237382A1 Substituted 6- and 7-amino-tetrahydroisoquinolinecarboxylic acids
11/13/1998	CA2230971A1 G-protein coupled receptor (hofnh30)
11/12/1998	WO1998050552A1 Novel tumor antigens
11/12/1998	WO1998050540A1 MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE
11/12/1998	WO1998050530A2 Enzymatic nucleic acids: synthesis, selection and use
11/12/1998	WO1998050527A1 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
11/12/1998	WO1998050435A1 Immunotoxins, comprising an onc protein, directed against malignant cells
11/12/1998	WO1998050433A2 Human monoclonal antibodies to epidermal growth factor receptor
11/12/1998	WO1998050432A1 Recombinant antibody-enzyme fusion proteins
11/12/1998	WO1998050424A2 Human serine protease precursor
11/12/1998	WO1998050420A1 Serine protease inhibitors
11/12/1998	WO1998050419A2 4-aza-steroids as inhibitors of testosterone-5-alpha-reductase
11/12/1998	WO1998050415A1 Pregnane 3,2o diol mono- and di-sulphates
11/12/1998	WO1998050413A1 Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens
11/12/1998	WO1998050412A1 Estrogenic 19-noradnrost-17-one derivatives with an aromatic b-ring
11/12/1998	WO1998050411A1 Pharmaceutically acceptable salts of 5alpha-pregnan-3beta, 16alp ha-diol-20-one 3-sulfate useful as progestins and cns disorders
11/12/1998	WO1998050410A1 Salts of 5.alpha.-pregn-16-en-3.beta.-ol-20-one 3-sulphate ester with progestin activity
11/12/1998	WO1998050397A2 Chimeric oligonucleotides and the use thereof
11/12/1998	WO1998050387A1 Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
11/12/1998	WO1998050386A1 A new class of benzoporphyrin derivative photoactive compounds
11/12/1998	WO1998050370A1 Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
11/12/1998	WO1998050365A1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
11/12/1998	WO1998050356A1 2-indolinone derivatives as modulators of protein kinase activity
11/12/1998	WO1998050073A1 Integrin ligand, human mindin
11/12/1998	WO1998050063A1 Method of treating hyperprolactinemia and prolactinomas
11/12/1998	WO1998050058A1 Complex formation between dsdna and oligomer of heterocycles
11/12/1998	WO1998050042A1 Pregnan-3-ol-20-ones
11/12/1998	WO1998050031A1 Inhibitors of protein isoprenyl transferases
11/12/1998	WO1998050030A1 Inhibitors of protein isoprenyl transferases
11/12/1998	WO1998050029A1 Inhibitors of protein isoprenyl transferases
11/12/1998	WO1998050016A2 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
11/12/1998	WO1998049897A1 Beta lactams as antiproliferative agents
11/12/1998	CA2299455A1 Complex formation between dsdna and oligomer of heterocycles
11/12/1998	CA2289742A1 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
11/12/1998	CA2289705A1 Beta lactams as antiproliferative agents
11/12/1998	CA2289118A1 Novel tumor antigens
11/12/1998	CA2289115A1 Recombinant antibody-enzyme fusion proteins
11/12/1998	CA2289108A1 Salts of 5.alpha.-pregn-16-en-3.beta.-ol-20-one 3-sulphate ester with progestin activity
11/12/1998	CA2289102A1 2-indolinone derivatives as modulators of protein kinase activity
11/12/1998	CA2289096A1 Pharmaceutically acceptable salts of 5alpha-pregnan-3beta, 16alpha-diol-20-one 3-sulfate useful as progestins and cns disorders
11/12/1998	CA2289095A1 Pregnane 3,20 diol mono- and di-sulphates
11/12/1998	CA2289025A1 Human serine protease precursor
11/12/1998	CA2289008A1 Estrenes
11/12/1998	CA2289006A1 Pregnan-3-ol-20-ones
11/12/1998	CA2288999A1 B-ring estratrienes
11/12/1998	CA2288946A1 Modified antisense nucleotides complementary to a section of the human ha-ras gene
11/12/1998	CA2288778A1 Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
11/12/1998	CA2288640A1 Enzymatic nucleic acids: synthesis, selection and use
11/12/1998	CA2288330A1 Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases
11/12/1998	CA2288232A1 Immunotoxins directed against malignant cells
11/12/1998	CA2287924A1 4-aza-steroids as inhibitors of testosterone-5-alpha-reductase
11/12/1998	CA2287569A1 Serine protease inhibitors
11/11/1998	EP0877083A1 A novel human G-protein coupled receptor (HCEPT09)
11/11/1998	EP0877030A2 EPO primary response gene 1,(EPRG1)
11/11/1998	EP0877019A1 Substituted diaminocarboxylic acid
11/11/1998	EP0877018A1 Sulfonylaminocarboxylic acids
11/11/1998	EP0876611A1 Molecules that home to a selected organ or tissue in vivo and methods of identifying same
11/11/1998	EP0876507A2 MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C - PP2C$g(a) - EXPRESSION IN TUMOR CELLS FOR CANCER THERAPY, PREVENTION AND DETECTION
11/11/1998	EP0876486A2 Murine monoclonal anti-idiotype antibody 11d10 an methods of use thereof
11/11/1998	EP0876482A1 Il-13 receptor polypeptide
11/11/1998	EP0876395A1 INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
11/11/1998	EP0876387A1 Method to improve the biological and antiviral activity of protease inhibitors

1 ... 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 ... 2211